Free tool
FAERS Monitor: Maxitrol
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 050023 or its brand name (Maxitrol, Dexamethasone, Neomycin Sulfate, Polymyxin B Sulfate). Reports on generic versions are filed under their own applications.
Reports
884
Serious
628
71% of reports
Hospitalization
223
Death reported
47
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- eye pain71
- pain47
- off label use45
- headache44
- vision blurred44
- visual impairment41
- eye irritation40
- drug ineffective39
- fatigue37
- ocular hyperaemia37
- dyspnoea35
- anxiety34
- intraocular pressure increased33
- ulcerative keratitis32
- dizziness31
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 6 |
| 2005 | 2 |
| 2006 | 6 |
| 2007 | 14 |
| 2008 | 7 |
| 2009 | 12 |
| 2010 | 21 |
| 2011 | 5 |
| 2012 | 20 |
| 2013 | 30 |
| 2014 | 33 |
| 2015 | 42 |
| 2016 | 92 |
| 2017 | 38 |
| 2018 | 58 |
| 2019 | 67 |
| 2020 | 73 |
| 2021 | 48 |
| 2022 | 66 |
| 2023 | 78 |
| 2024 | 65 |
| 2025 | 58 |
| 2026 | 43 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,053,275 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| ulcerative keratitisSignal | 32 | 281.2 | 199.7 | 8,557 |
| intraocular pressure increasedSignal | 33 | 61.6 | 44.1 | 1,903 |
| eye painSignal | 71 | 30.0 | 24.0 | 1,963 |
| ocular hyperaemiaSignal | 37 | 18.6 | 13.5 | 598 |
| eye irritationSignal | 40 | 16.5 | 12.2 | 570 |
| visual impairmentSignal | 41 | 7.9 | 5.8 | 241 |
| vision blurredSignal | 44 | 7.6 | 5.7 | 248 |
| anxietySignal | 34 | 2.8 | 2.0 | 39 |
| pain | 47 | 1.8 | 1.4 | 17 |
| headache | 44 | 1.7 | 1.3 | 12 |
| dizziness | 31 | 1.5 | 1.0 | 4 |
| dyspnoea | 35 | 1.5 | 1.1 | 5 |
| off label use | 45 | 1.2 | 0.9 | 2 |
| fatigue | 37 | 1.1 | 0.8 | 0 |
| drug ineffective | 39 | 0.7 | 0.5 | 5 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.